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Abstract 
RACIAL DIFFERENCES IN BONE TURNOVER RATE AND 
HYPERPARATHYROIDISM IN HEMODIALYSIS PATIENTS. 
Wendy W. Lou and Margaret J. Bia 
Section of Nephrology, Department of Internal Medicine 
Yale University, School of Medicine, New Haven, CT 
This study was undertaken to determine whether there was a racial difference in 
bone turnover rates in hemodialysis patients. It was also done to confirm previous 
observations demonstrating a lower level of calcium tolerance in white compared to black 
hemodialysis patients. Fifty HIV-negative and HBsAg-negative subjects were grouped 
according to race: 31 black subjects (62%) and 19 white subjects (38%). Except for one 
patient who was not prescribed any phosphate binders, the rest of the patients were 
maintained on calcium carbonate, aluminum hydroxide, or both. The two groups were 
similar in mean age, duration on dialysis, dialysis membrane surface area, body mass index 
(BMI), serum albumin concentration, average serum bicarbonate concentration, percent 
females, percent wheelchair-bound/bed-ridden subjects, percent with diabetes mellitus, and 
percent with subtotal parathyroidectomy. 
Bone turnover was examined indirectly with serum alkaline phosphatase, 
osteocalcin, tartrate-resistant acid phosphatase, and intact parathyroid hormone (iPTH) 
levels. The mean iPTH (273±56.5pg/ml in black subjects vs 118±39.1pg/ml in white 
subjects, p=0.0286) and mean tartrate-resistant acid phosphatase (4.4±0.28U/1 in black 
subjects vs 3.3±0.27U/1 white subjects, p=0.0166) levels were significantly higher among 
the black patients compared to white patients. The mean osteocalcin (81.32±12.82ng/ml in 
black subjects vs 48.49±15.32ng/ml in white subjects) and mean alkaline phosphatase 
(153±20.8U/1 in black subjects vs 114±22.0U/1 in white subjects) levels tended to be 
higher among the black subjects compared to the white subjects. In addition, a greater 
proportion of black patients had osteocalcin levels higher than the upper limits of normal 
range (77.42% of black subjects vs 47.37% of white subjects, p=0.0290; 
normal<25ng/ml). The same was seen in average alkaline phosphatase (58.06% of black 
subjects vs 21.05% of white subjects, p=0.0180; normalcl 14U/1) measurements. Taken 
as an aggregate, these results suggested that the black hemodialysis patients had a higher 
bone turnover rate than the whites. 

The groups had similar dietary calcium and phosphorus intakes, oral 1,25- 
dihydroxy vitamin D dose, blood 1,25-dihydroxyvitamin D levels, dialysate calcium 
concentrations, ionized serum calcium levels, total serum calcium levels, serum phosphate 
levels, and number of hypercalcemic episodes. However, black subjects did have a 
significantly higher mean elemental calcium dose of calcium carbonate than the white 
subjects did (elemental calcium content for black and white subjects: 2330±366.4 vs 
1273±312.9g/day, respectively, p=0.05). There was also a greater percentage of black 
subjects who were ingesdng more than lg of elemental calcium per day compared to the 
white subjects (74.19% of black subjects vs 42.11% of white subjects, p=0.023). This 
suggested that, in comparison to the white hemodialysis patients, the black patients had a 
greater tolerance for calcium carbonate without becoming hypercalcemic. 
These results suggest that black hemodialysis patients did have a higher bone 
turnover rate than white patients and that this may explain black patients' ability to tolerate a 
greater daily dose of calcium carbonate. Since iPTH levels were significantly higher in 
black subjects, the results also suggest that black hemodialysis patients have a greater 
degree of secondary hyperparathyroidism than white patients, which may explain black 
patients' higher bone turnover rate. 
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1 
I. Introduction 
Chronic renal failure (CRF) is defined as the condition in which the mass of 
functioning kidney tissue is insufficient to meet the demands for the excretion of wastes, 
regulation of plasma biochemistry, and normal synthetic functions. The severity of renal 
failure may be graded according to the reduction of glomerular filtration rate (GFR) (180) 
and may also be clearly reflected in the resulting systemic derangement. 
Uremic _ Osteodystrophy 
Among the many clinical manifestations of end-stage renal disease is the 
development of uremic osteodystrophy. This metabolic bone disease of these uremic 
patients is subdivided into four subtypes. Though all four are likely to be present in 
variable degrees, one may be more prominent clinically. Hyperparathyroidism is universal 
among end-stage renal disease patients and may lead to osteitis fibrosa cystica. 
Osteomalacia or rickets may result from the inability to convert vitamin D to its active 
metabolite, 1,25-dihydroxyvitamin D in advance renal disease (high-turnover). Moreover, 
aluminum may accumulate in bone leading to a type of vitamin D-resistant rickets (low- 
turnover). With near complete inactivity at the bone surfaces, the aplastic charteristic 
marks the fourth type of uremic osteodystrophy. In addition, other factors such as chronic 
acidosis and poor nutrition contribute to osteoporosis in these patients. 
That renal failure contributes multiple factors to the pathogenesis of these disease 
states is evident. Of particular interest here is hyperparathyroidism of chronic renal failure 
resulting from the kidney's inability to catabolize parathyroid hormone and phosphate 
retention as well as elevated serum calcium set point for parathyroid hormone secretion. 
Phosphate Retention 
As kidney disease progresses and GFR falls below 25 ml/min, hyperphosphatemia 
is common (37, 73). By means of multiple mechanisms, hyperphosphatemia is partially 
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responsible for the development of secondary hyperparathyroidism (166, 167, 168), 
dialytic bone diseases (35), and soft tissue calcifications (132) all of which are widely seen 
in hemodialysis patients. The involvement of phosphorus in hyperparathyroidism has been 
demonstrated in studies of oral phosphorus loading (151), long-term feeding of a high- 
phosphate diet (85), dietary phosphate restriction proportional to GFR reduction (168), and 
other manipulations of a similar nature (97, 100). In fact, Fournier, et al. (63) found a 
positive correlation between serum immunoreactive parathyroid hormone (iPTH) and the 
degree of hyperphosphatemia in dialysis patients. 
Hyperphosphatemia can lead to secondary hyperparathyroidism by decreasing 
serum calcium concentration. Acute elevation of serum phosphate level tends to decrease 
serum calcium level as the body attempts to maintain a constant calcium-phosphate product 
(181). The resulting low serum calcium level acts as a stimulus for parathyroid hormone 
(PTH) secretion. Phosphate retention also inhibits the activity of 25-hydroxy vitamin D-l- 
alpha-hydroxylase of the kidney and therefore contributes to the already altered vitamin D 
metabolism of renal disease (143). As shown by metabolic balance studies monitoring 
fecal calcium loss (91, 174) as well as isotopic methods (36, 134), the decreased 
production of 1,25-dihydroxyvitamin D is associated with low intestinal calcium absorption 
and thus contributes to a low serum calcium level. In addition, 1,25-dihydroxyvitamin D 
itself directly suppresses the secretion of PTH (25, 30, 52, 103, 125, 154, 163, 164, 169). 
It follows that a low plasma level of 1,25-dihydroxyvitamin D can decrease the sensitivity 
of parathyroid glands to the normal inhibitory effects at any given serum level of ionized 
calcium (127), thus contributing to the pathogenesis of secondary hyperparathyroidism via 
this abnormal calcium set point. Finally, deficiency in 1,25-dihydroxyvitamin D 
production along with phosphate retention leads to skeletal resistance to the calcemic action 
of parathyroid hormone (PTH) (56, 98, 108). Clearly, hyperphosphatemia, 1,25- 
dihydroxyvitamin D deficiency, and skeletal resistance to the calcemic effects of PTH all 
contribute to the decease in serum calcium concentration which in turn stimulates PTH 
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secretion and leads to secondary hyperparathyroidism. 
Secondary Hyperparathyroidism (Table 1) 
Slatopolsky and colleagues (168) have suggested that secondary 
hyperparathyroidism in chronic renal disease begins with the first stage of renal functional 
impairment and worsens with increasing loss of nephron population. If phosphorus intake 
is not reduced during the progression of chronic renal disease, a transient 
hyperphosphatemia would result and would temporarily lower serum ionized calcium level, 
which would then stimulate PTH secretion. Through phosphaturia, the serum phosphorus 
and calcium concentrations are brought back to normal at the expense of an elevated serum 
PTH level. Postulating this vicious cycle as the generator of secondary 
hyperparathyroidism, Slatopolsky and co-workers found that the onset of secondary 
hyperparathyroidism in experimental chronic renal disease can be delayed or perhaps even 
prevented by reducing dietary phosphorus intake proportional to the decrease in GFR 
(168). These effects of dietary phosphorus restriction are also supported by the 
observation that blood levels of 1,25-dihydroxyvitamin D inversely and iPTH directly vary 
with dietary phosphorus intake and that 1,25-dihydroxyvitamin D increases and iPTH 
decreases under phosphorus intake restrictions (143). 
The consequences of secondary hyperparathyroidism are numerous and complex. 
Among the conditions that result from this complication are soft tissue calcification (132) 
due to a high plasma calcium-phosphate product, and renal osteodystrophy (specifically 
osteitis fibrosa characterized by an increase in bone resorption, the number of osteoclasts, 
and marrow fibrosis) (35, 185). 
Reduction of Intestinal Phosphate Absorption 
Since phosphate retention can lead to secondary hyperparathyroidism, renal 
osteodystrophy, and extra-skeletal calcification, the prevention of hyperphosphatemia is 
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critical in the management of chronic renal failure patients. For patients with chronic renal 
failure, hemodialysis is usually conducted three times a week in the United States and may 
improve hyperphosphatemia. Although hemodialysis may serve as an adequate substitute 
for renal function with respect to the serum concentrations of many other ions, it is 
insufficient in maintaining an acceptable serum phosphate concentration on a daily basis. 
Therefore, a reduction in intestinal phosphate absorption is necessary and can be achieved 
by two methods: restriction of dietary phosphate content and use of phosphate-binding 
agents. Although it is possible to decrease dietary phosphorus intake to as low as 700- 
900mg/day (60% of normal) by a diet that is low in meats and dairy products (90), intakes 
lower than this are extremely difficult to achieve by dietary restriction alone. Therefore, for 
patients with advanced renal disease, orally administered phosphate-binding compounds 
are usually necessary to control hyperphosphatemia and to prevent secondary 
hyperparathyroidism (63, 64, 65). 
For many years, various orally administered aluminum salts have been used as 
effective phosphate binders in the gastrointestinal tract. However, at a dose sufficiently 
high to prevent hyperphosphatemia in most patients, a small amount of aluminum is usually 
absorbed. Consequently, therapies with aluminum-containing compounds can often lead to 
an elevated plasma and tissue aluminum content (3, 38, 99), anemic conditions (24, 86, 
113, 136, 184), dialysis encephalopathy (3, 51, 142, 162), and renal osteodystrophy (7, 
29, 51, 59, 136, 141, 189) in these patients. 
Calcium Carbonate 
In a search of alternatives to aluminum-containing phosphate binders, various 
investigators have conducted trials using such compounds as magnesium hydroxide (75, 
126), calcium carbonate (75), calcium citrate (44), and calcium acetate (44, 159). Though 
some controversies concerning their effectiveness and side effects remain (75, 120, 126, 
159), the most popular and currently believed to be the best replacement for aluminum- 
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containing phosphate binders is calcium carbonate (65). High doses of calcium carbonate 
taken by uremic patients may have three potential positive effects: binding of phosphates in 
the gut so that less dietary phosphates are absorbed; increasing passive calcium absorption 
from the gastrointestinal tract by increasing total oral calcium intake; and possibly 
contributing to the correction of metabolic acidosis (9, 121). 
Studies that support orally administered calcium carbonate as an effective phosphate 
binding agent are numerous. Clarkson and colleagues (33) demonstrated that patients with 
chronic renal failure taking high doses (20g/day) of oral calcium carbonate decreased their 
gastrointestinal absorption of phosphorus. Moriniere, et al. (122) observed that high dose 
calcium carbonate (5-20g/day) in hemodialysis patients can correct hyperaluminemia and 
control hyperphosphatemia. Studies undertaken by Addison, et al. (2), Fournier, et al. 
(66), Hercz, et al. (79), and Slatopolsky, et al. (170) all showed that calcium carbonate 
effectively controlled hyperphosphatemia and improved hypocalcemia, while Andreoli, et 
al. (6) and Salusky, et al. (156) published similar findings in their studies on children with 
chronic renal failure. Mak's crossover study of aluminum hydroxide or calcium carbonate 
therapy in children with chronic renal failure under dietary phosphate restriction revealed 
that both phosphate binding agents are able to suppress existing secondary 
hyperparathyroidism (104). In fact, Ramirez, et al. (146) concluded that calcium carbonate 
reduced gastrointestinal phosphorus absorption as much as aluminum hydroxide did. 
Other investigators focused on the effects of high dose calcium carbonate on 
calcium homeostasis in patients with chronic renal failure. Clarkson, et al. (34) showed 
that patients with chronic renal failure receiving 20g of calcium carbonate per day had a 
positive calcium balance and a reduced phosphate absorption. However, the phosphate 
balance was positive because the decrease in urinary phosphate excretion greatly surpassed 
the decrease in gastrointestinal phosphate absorption. Thus, they suggested that the 
observed reduction in plasma phosphate could be due to the decreased phosphate 
absorption and the the precipitation of calcium phosphate extra-skeletally. However, other 
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investigators (43, 117) found that high-dose oral calcium carbonate actually decreased bone 
resorption without increasing soft tissue calcifications. In fact, recovery from aluminum- 
related bone disease was observed by Hercz, et al. (80) when calcium carbonate was 
substituted for aluminum-containing phosphate binders. Furthermore, Renaud, et al. (152) 
observed that the doses of calcium carbonate are not covariant with the severity of 
metastatic calcification, as would be expected according to Clarkson's explanation. These 
findings are consistent with the idea that calcium phosphate precipitates mainly in the bone 
rather than in the soft tissues. 
Two other potential benefits of high dose calcium carbonate were demonstrated by 
Makoff and co-workers in their study of chronic calcium carbonate therapy in non-dialyzed 
uremic patients (105). As uremic patients usually suffer from chronic negative calcium 
balance and metabolic acidosis, the subjects received 3-7g/day of calcium carbonate for 3- 
12 months and showed a steady increase in serum calcium and bicarbonate levels. 
Symptomatically, several patients also noticed the disappearance of anorexia, nausea, 
fatigue, vomiting and neuromuscular irritability. The studies of Anelli, et al. (9), Berlyne 
(14), Clarkson, et al. (33), and Moriniere, et al. (121) revealed similar results dialysis 
patients, although the improvement in metabolic acidosis was not observed in Berlyne's 
investigation (14). 
The above accounts for many of the beneficial effects of orally administered calcium 
carbonate in chronic dialysis patients. However, this phosphate binding agent is not 
without side effects. Three complications of calcium carbonate administration were 
suggested by Raine and Oliver (145): 1) potential rebound increase in gastric acid secretion 
after calcium carbonate administration 2) extraosseous calcification, and 3) calcium 
carbonate doses insufficient as phosphate binders still often resulted in significant 
hypercalcemia. The first possible effect is theoretically hazardous in patients with end- 
stage renal disease since they have an increased incidence of peptic ulceration. 
Extraosseous calcification or soft tissue calcification and its many debilitating 
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sequelae had long been documented in hemodialysis patients (132). Calcium carbonate 
therapy may exacerbate the development and manifestations of soft tissue calcification (23). 
However, the majority today believe it to be a problem. Hypercalcemia as the main side 
effect of high dose calcium carbonate therapy has been noted by many investigators (66, 
71, 79, 101, 102, 106, 122, 156, 170). During Stein's twelve month observation of 
approximately 150 hemodialysis patients on 1.5-4g of calcium carbonate per day (176), 
there were 11 cases of mild to severe hypercalcemia — associated with pancolonic 
impaction in two patients and worsening hypertension in one patient. Increasing 
weakness, nausea, confusion, pruritis, and milder degrees of constipation were noted in 
the others. However, Fournier, et al. (66) reported that about half of the patients in whom 
calcium carbonate successfully controlled hyperphosphatemia encountered hypercalcemia. 
The reported incidence of hypercalcemia varies from 27 to 53 percent of dialysis patients on 
high-dose calcium carbonate therapy (66, 71, 101, 106, 122, 170). 
Hypercalcemia 
Causes of Hypercalcemia (Table 2) 
Patients are usually considered hypercalcemic if their serum calcium levels rise 
above 10.5mg/dl (171). In the general population, the clinical manifestations of 
hypercalcemia depend partly on the underlying disease. Mild to moderate hypercalcemia is 
often asymptomatic, but there may be mild disturbances in renal, gastrointestinal, central 
nervous, or other systems (178). Confusion, obtundation, weakness, and dehydration 
may be features of more severe hypercalcemia (124). Population studies in England (124) 
and in the United States (78) showed similar incidences of hypercalcemia - approximately 
40 per 100,000 persons a year, of whom about 25 per 100,000 a year have primary 
hyperparathyroidism. Another study in England (62) revealed different figures for the 
causes of hypercalcemia among hospital patients : 47 percent had malignant disease, 13 
percent had hyperparathyroidism, 15 percent were dialyzed, and 22 percent showed no 
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apparent cause. All other known causes amounted to less than 5 percent. 
Parfitt (133) divided hypercalcemia into equilibrium types and disequilibrium types. 
Coburn and Slatopolsky (35) included a third group, the hyperabsorptive types, which 
share characteristics of both equilibrium and disequilibrium types. Equilibrium 
hypercalcemia, typified by chronic hyperparathyroidism, has a stable serum calcium 
concentration over time and a zero calcium balance. Since bone resorption may be normal, 
this hypercalcemia is not sustained by a net increase in calcium release from the bone, but 
by a PTH-induced shift in the plasma-bone equilibrium at quiescent bone surfaces, where 
the net calcium exchange remains zero. In hyperparathyroidism, calcitriol levels may be 
raised, leading to an increased calcium absorption from the gut. Moreover, PTH promotes 
tubular calcium reabsorption so that calcium excretion at the elevated serum calcium 
concentration balances the net intestinal absorption. In addition, tumors may also cause 
equilibrium hypercalcemia by producing PTH-like compounds which act to increase bone 
resorption and renal calcium reabsorption (88). 
Disequilibrium hypercalcemia, on the other hand, is characterized by an unstable 
serum calcium concentration which tends to increase gradually. There is a pathologic 
increase in the net bone resorption which may be due to multiple myeloma (123) or 
metastatic carcinoma, for example. Furthermore, renal calcium excretion is decreased by 
reduced glomerular filtration rate (GFR) as a result of hypercalcemia, sodium depletion, 
and volume contraction. Thus, a vicious cycle of elevating plasma calcium levels proceeds. 
Severe hyperparathyroidism with extensive bone resorption (for example, as a result of 
large or malignant parathyroid tumors) or reduction in renal calcium excretion, as with 
volume depletion or the use of thiazide diuretics (17), can lead to disequilibrium 
hypercalcemia. 
Finally, hyperabsorptive hypercalcemia may be associated with vitamin D 
intoxication (45, 157), sarcoidosis (10), the milk-alkali syndrome (87, 129), and 
hyperparathyroidism. Here, because of alkalosis, volume depletion, or perhaps the 
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elevated vitamin D level, intestinal calcium absorption is increased, renal calcium 
reabsorption is usually increased, and net bone resorption may also be increased (179). 
A list of some clinical causes of hypercalcemia appears in Table 2. 
Hypercalcemia in Chronic Renal Failure 
The symptoms of hypercalcemia at a given semm calcium level may be more severe 
in uremic patients than in patients with normal renal function (35). Therefore, it is 
important to determine the causes of hypercalcemia in patients with chronic renal failure 
(Table 3). Persistent hypercalcemia is mainly a consequence of severe secondary 
hyperparathyroidism and/or aluminium-related bone disease, both of which are commonly 
seen in chronic dialysis patients. Hypercalcemia in patients with severe secondary 
hyperparathyroidism can develop within a few months or after several years of dialysis. 
One possible reason for the appearance of hypercalcemia may be that dialysis patients are 
more resistant to the suppression of PTH secretion by elevated serum calcium level (35). 
Brown and co-workers (19) observed that a marked elevation of calcium set point is 
common in patients with advanced renal failure and secondary hyperparathyroidism. The 
set point is defined by the calcium concentration necessary to suppress PTH secretion from 
parathyroid cells by 50-percent. The change in the set point may be responsible for the 
hypercalcemia. Another explanation for the high levels of PTH secretion may be the 
existence of massive parathyroid hyperplasia in the presence of an elevated serum calcium 
concentration. 
A second condition that may lead to hypercalcemia in dialysis patients is aluminum- 
related bone disease (161). The deposition of aluminum in bone is associated with 
mineralization defects (60). Boyce and colleagues found that 14 of their 16 patients with 
aluminum-related osteomalacia were hypercalcemic. They also suggested that the 
aluminum at calcification sites interferes with the proper mineralization of osteoid. Since 
calcium can not be incorporated into bone, the body's largest reservoir of calcium 
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(normally containing over 99% of the total body calcium) (92), it remains extra-skeletally 
and causes hypercalcemia. 
Transient hypercalcemia may also occur or preexisting hypercalcemia may be 
aggravated in patients who receives large doses of calcium salts during vitamin D sterol 
treatment and after being dialyzed against a calcium concentration of 7-8mg/dl (149). 
Other causes of hypercalcemia in dialysis patients may include the use of calcium- 
containing cation-exchange resins (131), thiazide diuretics (89), hypophosphatemia due to 
phosphate restriction, excessive vitamin D, and immobilization (69, 130, 177). 
In addition, the frequency of hypercalcemia appears to vary with different types of 
renal osteodystrophy. Cochran, et al. (40) studied twenty-two dialysis patients according 
to the presentation of bone disease: 12 patients had atypical osteomalacia and had fractures 
most likely resulting from aluminum toxicity. All patients were prescribed 600mg oral 
calcium carbonate per day (except in those who developed hypercalcemia) but no vitamin D 
supplements. The average plasma phosphorus level was lower in the fracture group, 
though not statistically significant, compared to the other group. Members of the fracture 
group also had greater fluctuations in the plasma calcium concentration and more frequent 
spontaneous hypercalcemic episodes than those with secondary hyperparathyroidism. This 
difference in plasma calcium levels was believed to stem from the difference in the bone 
turnover rates. As reflected in the elevated alkaline phosphatase levels, the secondary 
hyperparathyroidism group had a higher bone formation rate compared to the fracture 
group. When the plasma calcium level is elevated, for example, from dialysis or 
gastrointestinal absorption, the reduced mineralization activity in the fracture group is not 
capable of rapidly incorporating the excess plasma calcium into bone and thus allows 
hypercalcemia to persist. 
A study conducted by Piraino and co-workers (139) compared the nature of bone 
disease in 30 normocalcemic dialysis patients against 10 dialysis patients with spontaneous 
hypercalcemia who were receiving neither calcium nor vitamin D supplements. There was 
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no significant difference between the two groups in the mean age, sex, race ratios, duration 
of dialysis, type of dialysis, percent of patients with mineralization defects, and serum 
albumin, phosphorus, alkaline phosphatase, and parathyroid hormone levels. Bone pain as 
rated by a disability scale was more severe in hypercalcemics than normocalcemics; and 
osteomalacia and bone aluminum staining were more dramatic in the hypercalcemic 
patients. Moreover, the stainable bone aluminum level correlated negatively with 
mineralization activity and positively with serum calcium concentration. In hypercalcemics, 
polycystic kidney disease and other congenital-hereditary diseases were more common 
causes of chronic renal failure (80%) than in normocalcemics (20%). Although 1,25- 
dihydroxyvitamin D levels were not measured in their study, the investigators suggested 
that more 1,25-dihydroxyvitamin D may be produced by polycystic kidneys than other end- 
stage disease kidneys and may explain the difference. 
Piraino, et al. (141) compared 21 hypercalcemic dialysis patients without vitamin D 
or calcium therapy and 28 non-hypercalcemic dialysis patients. Bone biopsies determined 
that two-thirds of the hypercalcemia patients had low-turnover osteodystrophy (mostly 
osteomalacia), and hypercalcemic patients with osteitis fibrosa had a significantly lower 
mean N-terminal PTH level than the non-hypercalcemics with osteitis fibrosa did. 
Hypercalcemia Associated with Calcium Carbonate Therapy 
Hypercalcemia during calcium carbonate therapy has been observed by numerous 
investigators. When calcium carbonate was started or increased in hemodialysis patients, 
Gonella, et al. (74) observed that significant hypercalcemia especially in patients who had 
normal predialysis serum phosphate levels and who did not receive aluminum hydroxide 
before the calcium carbonate therapy. It was suggested that these patients may have had a 
higher level of 1,25-dihydroxyvitamin D, whose formation would be inhibited by 
hyperphosphatemia, although vitamin D levels were not reported. This greater availability 
of 1,25-dihydroxyvitamin D may allow increased gastrointestinal calcium absorption and 
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thus hypercalcemia to occur. In a year-long study of 12 children with chronic renal failure, 
Mak and co-workers (104) did not observe hypercalcemia until several months after the 
initiation of calcium carbonate therapy and did not find it to be more common with calcium 
carbonate than with aluminum hydroxide. Therefore, the investigators suggested that the 
altered vitamin D metabolism as a consequence of controlling phosphate retention is 
responsible for the hypercalcemic episodes. 
From a study of 10 hemodialysis patients receiving 3.2-6.4g calcium carbonate (or 
1.28-2.56g elemental calcium) per day for 4-8 weeks, Ginsburg, et al. (72) concluded that 
the hypercalcemia resulted from the intestinal absorption of calcium because they observed 
a prompt recovery from hypercalcemia and remission of symptoms upon the withdrawal of 
calcium carbonate therapy. Moreover, Slatopolsky and colleagues noted that hypercalcemia 
occurred mainly in those patients who received high oral calcium carbonate doses (>12g 
calcium carbonate/day, or >4.8g elemental calcium carbonate) because of their high 
phosphorus intake. This observation suggests that high calcium carbonate doses are 
responsible for the elevated serum calcium concentration. 
In contrast, Mactier and co-workers (101) found that hypercalcemic patients did not 
receive higher calcium carbonate doses and did not have a higher serum aluminum or 
parathyroid hormone levels than the other hemodialysis patients in their study. 
Hercz, et al. (81) studied 29 dialysis patients on 3-10g calcium carbonate (with 
40% elemental calcium) per day and found hypercalcemic episodes in 12 patients. Of 
these, 10 had bone biopsies and 9 showed aluminum-related bone disease. Andreoli, et al. 
(6) reported improvement in a case of calcium carbonate intolerance manifesting 
hypercalcemic symptoms in an infant after the resolution of his severe aluminum-induced 
bone disease. 
Bia and Meric's Study of Hvnercalcmia in Dialysis Patients 
Meric and Bia (116) set out to characterize the risk factors of hypercalcemia in 
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dialysis patients on high-dose calcium carbonate therapy. Fourteen hypercalcemic patients 
were compared with 14 eucalcemic patients matched for age, sex, duration of dialysis, and 
etiology of kidney disease. The two groups were similar in terms of calcium carbonate 
dosage, dietary calcium intake, plasma levels of vitamin D metabolites, and aluminum 
burden; but compared to the eucalcemics, the hypercalcemics had significantly lower bone 
turnover rates as reflected by their lower serum osteocalcin, intact PTH, and alkaline 
phosphatase levels. Thus, there was no evidence that the hypercalcemics had greater active 
intestinal calcium absorption, although the latter was not directly measured. However, 
the results did show an association between hypercalcemia and low bone 
turnover rate, therefore supporting the notion that patients with low bone 
turnover rates are less able to move calcium out of the circulation quickly 
enough to prevent hypercalcemia. Another observation noted by the investigators is 
of special interest: While the dialysis unit at which the study was conducted consisted of 
36% white patients, 64% of the hypercalcemic patients were white while only 14% of the 
eucalcemic patients were white. Therefore, there appeared to be a significant 
difference in bone turnover rate and calcium tolerance level between black 
and white hemodialysis patients. 
Racial Differences of Bone Metabolism in the Healthy Population 
Racial differences in bone density and metabolism have been documented (42). 
Black subjects tend to have a higher bone density than white subjects by 5-10%. (This 
difference is also observed in the population with chronic renal failure) (110). In the 
healthy population, this is attributable to a greater increase in bone growth during the 
pubertal spurts in black individuals than in white individuals (70), and to the lower bone 
turnover rate (only about 35% of that in white subjects) in the black subjects (191). Higher 
PTH levels have been found in normal black subjects compared to white subjects (11), but 
similar levels were observed in other studies (115). The higher PTH levels in these black 
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subjects were associated with lower osteocalcin levels sugggesting resistance to the effects 
of PTH. 
Aside from the observations in Bia and Meric's study, there have not been any 
reports on racial differences in bone turnover or on calcium tolerance on chronic dialysis 
patients at the time of this study. 
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II. Purpose 
Meric and Bia observed that hypercalcemia occurred more commonly in 
hemodialysis patients with low bone turnover. Furthermore, their results suggest that this 
phenomenon occurred more commonly in white versus black hemodialysis patients. The 
current investigation was designed to determine whether there actually is 
such a racial difference in indirect measures of bone turnover rate in 
hemodialysis patients. In the process, this study would also confirm or disprove their 
previous observation that calcium tolerance is greater in black than in white hemodialysis 
patients. 
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III. Materials and Methods 
Patient Population (Table 4) 
At the time of this investigation, the Yale-New Haven Dialysis Unit was treating a 
total of 58 patients with chronic hemodialysis, who were potential candidates for this 
study. Chronic hemodialysis was defined as having been on dialysis for at least one month 
before this investigation and having no expectation of recovering physiological renal 
function. Because of the nature of our question and hypothesis, only white and black 
patients were chosen; the numbers of Asians, Hispanics, or patients of other descents were 
too small to be included. In addition, those with HIV-positive or HBsAg-positive status 
were also excluded. The unit had three Hispanic patients, one of whom was HBsAg- 
positive, and one HIV-positive patient. Of the 54 remaining patients, 50 gave oral consent 
to participate and formed the patient population of this investigation. None of these patients 
had any evidence of metastatic cancer which might be a confounding cause of 
hypercalcemia. Therefore, fifty HIV-negative, HBsAg-negative, and white or black 
chronic hemodialysis patients were evaluated for their bone turnover rate in this study. 
The following summary of the patient characteristics was true not only at the time of 
this study but also for at least one month immediately prior to it. All, except one, of the 50 
subjects underwent hemodialysis three times a week at Yale-New Haven Hospital. One 
white, male patient diagnosed with renal failure required only two dialysis treatments per 
week, but he was not expected to recover his own physiologic renal function and therefore 
will continue to rely on hemodialysis. The patients at the unit were dialyzed against a 
calcium bath of either 2.5mEq/l or 3.5mEq/l. Oral phosphate binders (aluminum- 
containing binder(s) and/or oral calcium-containing binders) were taken by all subjects 
except one who was not on any phosphate binders. The only form of oral vitamin D 
supplement for the patients was 1,25-dihydroxy vitamin D, and the patients were prescribed 
daily doses of 0.25qg, or 0.50pg. Postdialysis intravenous 1,25-dihydroxyvitamin D was 
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also prescribed when necessary as described in “Results” section of this thesis. 
Data Collection 
The following blood chemistry levels pertinent to our evaluation were obtained. 
These parameters were all measured predialytically on the same day for any given patient in 
this cross-sectional study. 
* Serum bicarbonate: a measure of the degree of metabolic acidosis in dialysis patients; 
* Plasma albumin: a sensitive measure of constitutional illness 
* Ionized calcium: the biologically active portion of total calcium; 
* Total calcium; 
* Total phosphate; 
* Intact parathyroid hormone: a measure of steady state parathyroid hormone level (112, 
173); 
* Plasma 1,25-dihydroxyvitamin D; 
* Alkaline phosphatase: an estimate of osteoblastic activity and thus of bone formation rate 
(28, 112); 
** Alkaline phosphatase cleaves, or hydrolyzes, pyrophosphate which is an 
inhibitor of bone mineralization (92) 
* Total serum acid phosphatase; 
* Prostatic acid phosphatase; 
** Tartrate-resistant acid phosphatase (bone fraction acid phosphatase) level was 
calculated by subtracting prostatic acid phosphatase level from total serum acid 
phosphatase level. It is released from osteoclasts during bone resorption (48, 119, 
128) (The validity of this subtraction method was confirmed by comparing the 
results of 10 random samples calculated by our method and obtained by direct 
measure of TRAP from the Jerry Pettis VA Medical Center endocrinology 
laboratory at Loma Linda, CA. A good correlation of these two methods was 
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evidence by linear regression analysis with R^ = 0.638 and p<0.0056.); 
* Osteocalcin: a product of osteoblasts and a measure of bone formation rate (20, 28) 
In addition to single serum measurements of these electrolytes, enzymes, and 
hormones for each of the 50 subjects, a chart review was performed to obtain serum levels 
of bicarbonate, albumin, alkaline phosphatase, total calcium, and total phosphate during the 
three months just before this study. Levels at the time of study are compared with the 
corresponding three-month averages to verify that the current values are reflective of the 
patient's general long-term status which ultimately affects her/his bone turnover rate. 
Furthermore, the record was reviewed for the following additional information 
about each patient: 
* Daily dietary calcium content calculated from a 24-hour dietary recall (138) by the Yale- 
New Haven Dialysis Unit dietician within the past six months; 
* Daily dietary phosphate content calculated from a 24-hour dietary recall (138) by the 
Yale-New Haven Dialysis Unit dietician within the past six months; 
* Dialyzer membrane surface area for at least one month just prior to this study; 
* Calcium concentration in the dialysate bath for at least one month just before to this 
study; 
* Daily oral intake of calcium from calcium-containing phosphate binders as prescribed for 
at least one month immediately prior to the time of this study unless specified; (Patients 
were given calcium carbonate, oyster shell calcium, Oscal500®, and/or Turns®.) 
* Daily oral intake of aluminum from aluminum-containing phosphate binders as 
prescribed for at least one month immediately prior to the time of this study unless 
specified; (Patients were given Amphojel® and/or Basaljel®.) 
* Daily oral intake of 1,25 dihydroxyvitamin D (Rocaltrol®) as prescribed for at least one 
month just before the time of this study; 
* Intravenous dose of 1,25 dihydroxyvitamin D (Calcijex®) administered for at least one 
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month just before the time of this study; 
Furthermore, the patients' activity levels were assessed with the assistance of Dr. 
Pepita Yap, the chief physician for the Yale-New Haven Dialysis Unit. For the purpose of 
this study, each subject was categorized as either being wheelchair-bound/bed-ridden or 
ambulatory. 
The review also provided each patient’s age, length of time on dialysis, race, sex, 
dry weight, height, as well as identified those with diabetes mellitus and those with 
parathyroidectomy (subtotal). Body mass index (BMI) was determined for each patient by 
dividing the dry weight (kg) by the squared height (m^). 
Laboratory Analyses 
The Yale-New Haven Chemistry Laboratory measured the serum levels of 
bicarbonate, albumin, ionized calcium, total calcium, phosphate, alkaline phosphatase, total 
acid phosphatase, and prostatic acid phosphatase. 
Intact parathyroid hormone (Nichols Institute Allegro Intact PTH Immunoassay — 
two-site immunoradiometric assay) and 1,25-dihydroxy vitamin D (Reinhold Method) 
levels were determined by Yale University, Mineral Metabolism Laboratories. 
Osteocalcin levels were measured by the 1125 Radioimmunoassay (bovine) in Dr. 
Caren M. Gundberg's laboratory, Yale University School of Medicine, Department of 
Orthopedics and Rehabilitation. 
After all the data were obtained, the 50 subjects were divided according to race, 
white or black, and the groups were then analyzed for their bone turnover rates, various 
calcium tolerance parameters, and episodes of hypercalcemia. Therefore, those performing 
the laboratory analyses were blinded to the subjects' demographic background. 
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Statistical Analyses 
Differences between the races in the parameters which consisted of continuous 
values were analyzed by the 2-tail Student's t-test (unpaired). In addition, using the 
respective upper limits of normal range as cutoff points, the parameters that reflect bone 
turnover rates were then converted to dichotomous variables for the 2x2 chi-square table 
and were also analyzed by chi-square analysis (or Fisher's exact test where appropriate). 
For the parameters that were originally dichotomous or nominal, only chi-square analysis 
(or Fisher's exact test) was used. Linear regression analysis was performed to determine 
the relationships between the various parameters measured. All data are presented as mean 
± SEM or as percentages. 
In addition, multivariate analyses were performed by general linear modelling 
procedures in IBM-PC SAS. This allowed for a closer look at the associations among 
variables and the factors that account for the predictable variabilities of certain parameters in 
the study. 
The student arranged for all the blood drawings, reviewed medical records, and 
collected current data of the subjects. She performed all data entry and statistical analyses 
according to the design of the study with consultations from James Jekel, MD, MPH of 
Yale University School of Epidemiology. With the guidance of her thesis advisor, 
Margaret Bia, MD, the results were further interpreted and thesis manuscript written. 
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IV. Results 
Demographic Data (Table 5) 
Fifty HIV-negative, HBsAg-negative chronic hemodialysis patients participated in 
this study: 31 blacks and 19 whites (i.e., 62% blacks and 38% whites). The subjects were 
divided into two groups according to race: blacks and whites. 
As shown in Table 5, the black and white patients were similar in their mean age, 
mean body mass index (BMI), mean length of time on dialysis, percent of subjects on 
dialysis longer than 6 months, that longer than 12 months, percent females, percent 
wheelchair-bound/bed-ridden subjects, percent with diabetes mellitus, and percent with 
subtotal parathyroidectomy. 
The Yale-New Haven Dialysis Unit dietician obtained a 24-hour dietary recalls from 
47 subjects. Twenty-one (67.74%) of 31 blacks and 12 (63.16%) of 19 whites actually 
provided recalls, and these percentages were not statistically different. Of the remaining, 
one black patient had psychiatric problems preventing her from giving an accurate 24-hour 
recall, and the rest of the patients reported themselves as poor historians who could not 
recollect their daily dietary intake. 
The patient groups also had comparable mean serum albumin levels (4.32 ± 
0.08g/dl in black vs. 4.06 ± 0.17g/dl in white patients). All women, except one white 
patient, were amenorrheic either due to their normal physiological menopause or due to 
their chronic renal failure and dialysis treatments; none received estrogen replacement 
therapy. The most recent subtotal parathyroidectomy in the unit was completed four 
months before this study. Although white patients had a slightly higher mean bicarbonate 
level (20.0 ± 0.55mmol/l in black subjects vs. 21.9 ± 0.74mmol/l in white subjects; 
p=0.0398), the two groups had similar mean values for the 3-month average 
(21±0.442mmol/l in black subjects vs. 22.2±0.542mmol/l in white subjects; p=NS). 
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Parameters of Bone Turnover Rate (Table 6, Figures 1, 2, 3, 4, & 5) 
The four key measurements of bone turnover rate in this study were serum alkaline 
phosphatase, osteocalcin (serum bone Gla-protein, S-BGP), tartrate-resistant acid 
phosphatase levels, and intact parathyroid hormone. Statistically higher concentrations of 
serum tartrate-resistant acid phosphatase (4.4 ± 0.28U/1 in black subjects vs. 3.3 ± 
0.27U/1 in white subjects; p=0.0166) (Figure 1) and intact parathyroid hormone (273 ± 
56.5pg/ml in black subjects vs. 118 ± 39.1pg/ml in white subjects; p=0.0286) (Figure 2) 
were found among the black subjects compared to that the white subjects. Although the 
mean serum alkaline phosphatase (153 ± 20.8U/1 in black subjects vs. 114 ± 22.0U/1 in 
white subjects) (Figure 3) and osteocalcin (81.32 ± 12.82ng/ml in black subects vs. 
48.49 ± 15.32ng/ml in white subjects) (Figure 4) concentrations tended to be higher in the 
black patients than in the white patients, the differences did not reach statistical 
significance. However, the proportion of patients with serum osteocalcin levels above 
25ng/ml was significantly higher among the black subjects than the white subjects (77.42% 
vs. 47.37%, respectively; p=0.0290) (Figure 5). The level of 25ng/ml was used since it 
is the upper limit of normal postmenopausal women, the group expected to have the highest 
levels in our subject population. There was a significantly higher percent of black patients 
having a 3-month average serum alkaline phosphatase levels higher than normal as 
compared to the whites (58.06% vs. 21.05%, respectively; p=0.0180). 
Each of the above four parameters reflecting bone turnover rate was statistically 
higher in blacks than in whites, either by t-test or chi-square analysis. Since the two 
groups had similar mean dialyzer membrane surface areas, these differences were probably 
not the result of filtration variability, but rather a reflection of difference in bone turnover 
rate. 
As mentioned above, plasma 1,25-dihydroxyvitamin D, known to have complex 
interactions with other bone turnover parameters, may activate bone resorption and may 

exert a direct anabolic effect on the osteoblasts (181). The two patient groups had similar 
mean plasma 1,25-dihydroxyvitamin D levels (Table 7). 
Semm Calcium and Phosphate-P Levels (Table 6) 
The total serum calcium concentration on the day of study was representative of 
each patient's average total semm calcium concentration for the 3 months of review. When 
the means for serum ionized calcium and total semm calcium concentrations were compared 
between the two patient groups, no significant difference was found. 
Likewise, there was also no significant difference in the means of these 
concentrations between the two patient populations. The serum phosphate-P level on the 
day of study was representative of the 3-month average serum phosphate-P level for each 
patient in the study. 
Parameters of Calcium Tolerance (Table 7, Figures 6 & 7) 
As mentioned above, the two racial groups in this study had similar mean serum 
ionized calcium and total serum calcium concentrations. However, black subjects had a 
significantly higher mean prescribed elemental calcium dose than white subjects (2330 ± 
366.4mg/day vs. 1273 ± 312.9mg/day, respectively; p=0.05) (Figure 6). Chi-square 
analysis showed a statistically greater proportion of black patients who ingested calcium 
carbonate doses containing more than lg of elemental calcium per day as compared to 
white patients (74.19% vs. 42.11%, respectively; p=0.023) (Figure 7). The percent of 
blacks whose doses contained more than 2g of elemental calcium per day also tended to be 
higher than that of whites, though the difference did not reach statistical significance 
(41.94% of black subjects vs. 15.79% of white subjects; p=0.0678). The two groups 
did not differ statistically on the percentages receiving oral aluminum hydroxide or the dose 
received. Likewise, the percentages receiving no phosphate binders were similar. The 
mean aluminum dose per day was similar in both groups as is the percentages receiving 
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more than lg of elemental aluminum per day in the form of aluminum hydroxide, and 
percentages receiving more than 2g of elemental aluminum per day. 
The two groups had comparable mean dietary calcium intakes, dialysate calcium 
concentrations, oral 1,25-dihydroxyvitamin D doses, and serum oral 1,25- 
dihydroxyvitamin D level. Similarly, the percent dialyzed against a 3.5mEq calcium per 
liter of bath (as opposed to a 2.5mEq/l bath), percent receiving oral 1,25-dihydroxyvitamin 
D supplementation, percent receiving greater than 0.25pg/day of oral 1,25- 
dihydroxyvitamin D, and percent with plasma 1,25-dihydroxyvitamin D level above 
65pg/ml were not different between the two subject populations. Only one black patient 
received 1 pig of Calcijex® (intravenous 1.25-dihydroxyvitamine D) twice a week 
postdialysis. Each patient group had two cases of hypercalcemia (6.45% of black subjects 
vs. 10.53% of white subjects; p=NS). [Hypercalcemia was defined as two or more 
measurements > 10.7mg.dl (2.7mmole/l), or a single value over 10.7mg/dl if it represented 
an increase of Img/dl (0.25mmol/l) over the average calcium value of the other 2 months of 
the 3-month review.] Lastly, the two groups also had similar mean dietary phosphorus 
intake 
Regression Analyses (Table 8) 
Osteocalcin was positively correlated with intact parathyroid hormone levels 
(r=+0.65484; p=0.0001), tartrate-resistant acid phosphatase (r=+0.59522; p=0.0001), and 
alkaline phosphatase (r=+0.40372; p=0.0036). There was also significant positive 
correlation between tartrate-resistant acid phosphatase and intact parathyroid hormone 
(r=+0.41709; p=0.0032). Furthermore, intact parathyroid hormone level was positively 
correlated with body mass index (BMI) (r=+0.41623; p=0.()033). 
In addition, the patients' dietary calcium intake tended to correlate negatively with 
their serum calcium level (r=-0.33471; p=0.0569). Doses of elemental calcium doses as 
calcium carbonate correlated positively with serum 1,25-dihydroxyvitamin D levels 
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(r=+0.47367; p=0.0005) and negatively with doses of oral 1,25-dihydroxyvitamin D 
(r=+0.45854; p=0.0008), but not with any measure of bone turnover. There was also 
positive correlation between serum 1,25-dihydroxyvitamin D levels and total serum calcium 
concentrations (r=+0.34120; p=0.0153). However, no correlation was observed between 
serum calcium level and elemental calcium dose or dietary calcium intake. 

26 
V. Discussion 
This study examined bone turnover rate and degree of calcium tolerance in black 
versus white hemodialysis patients from the Yale-New Haven Hospital Dialysis Unit. 
Bone turnover was analyzed indirectly via serum intact parathyroid hormone, tartrate- 
resistant acid phosphatase, osteocalcin, and alkaline phosphatase levels. Mean levels of 
intact parathyroid hormone and tartrate-resistant acid phosphatase were significantly higher 
and mean levels of osteocalcin and alkaline phosphatase tended to be higher in the black 
compared to the white patients. Additionally, a greater percentage of black subjects than 
white subjects had levels greater than upper limits of normal range for osteocalcin and 
alkaline phosphatase. 
On estimate of calcium ingestion, black patients had a significantly higher mean 
elemental calcium dose of calcium carbonate and a greater percentage ingesting more than 
lg/day of elemental calcium than white patients did. The two groups had similar ionized 
calcium levels, total serum calcium levels, number of hypercalcemic episodes, serum 
phosphate levels, dietary calcium and phosphate intakes, oral 1,25-dihydroxyvitamin D 
doses. 
Bone Turnover Rate 
The key question raised in the study was whether there was appreciable difference 
in bone turnover rates of black versus white hemodialysis patients. In order to examine 
this hypothesis, parameters which provided indirect measures of bone remodeling were 
examined: serum intact parathyroid hormone, serum alkaline phosphatase, serum 
osteocalcin, and serum tartrate-resistant acid phosphatase concentrations as well as plasma 
1,25-dihydroxyvitamin D level to some extent. Plasma 1,25-dihydroxyvitamin D appears 
to function in the dynamics of bone turnover (48, 119, 128), in addition to promoting 
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calcium absorption in the intestine,. The black and white subjects in this study had similar 
mean plasma 1,25-dihydroxyvitamin D levels. 
Black patients were found to have a significantly higher mean intact parathyroid 
hormone level than the white patients in this study. High parathyroid hormone levels tend 
to associate with high bone turnover rates with increased osteoblast and osteoclast numbers 
and increased bone formation and resorption (15, 35, 96). In the early stages of chronic 
renal disease, hyperphosphatemia and hypocalcemia are corrected at the expense of an 
elevated parathyroid hormone level (15, 83, 168, 172) which leads to phosphaturia and 
skeletal calcium release. As this cycle progresses, the parathyroid glands become less 
sensitive to the inhibitory effects of serum ionized calcium level (15, 168). As the negative 
feedback regulation between ionized calcium level and parathyroid secretion becomes less 
effective, massive hypertrophy or autonomy of the parathyroid glands tends to occur giving 
rise to high parathyroid hormone concentrations in the presence of hypercalcemia (175). 
Nevertheless, serum intact parathyroid hormone level is a indication of bone turnover. 
In this study, black subjects tended to have a higher mean serum alkaline 
phosphatase level and had a significantly greater percentage with serum levels above the 
upper limit of normal range in comparison to white subjects. Serum alkaline phosphatase 
originates primarily in the bone, liver, and placenta. In terms of bone metabolism, the bone 
fraction of this enzyme rises in proportion to osteoblastic activity (28, 61). Accordingly, 
elevated serum alkaline phosphatase concentrations are seem in high bone turnover 
conditions such as osteitis fibrosa (5), whereas low levels were found in low bone turnover 
osteomalacia (16, 26, 40, 51, 182). In fact, serum alkaline phosphatase concentration 
correlates positively with the activity level at bone turnover surfaces (53). In this study, 
none of the subjects were pregnant, and all had been watched for liver disease from their 
routine liver enzyme tests of ALT (SGPT), AST (SGOT), and bilirubin (direct and total) 
concentrations. Thus, elevations of serum alkaline phosphatase levels were interpreted as 
increases in bone formation in this study. 
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Black subjects also tended to have a higher mean serum osteocalcin level and had a 
significantly greater percentage with levels above the upper limit of normal range compared 
to the white subjects in this study. As a result of impaired renal clearance of osteocalcin 
(49) and increased osteoblastic (28) and osteoclastic activities (26, 57, 76, 107, 158), 
chronic renal failure patients are known to have an elevated serum osteocalcin (serum bone 
gamma-carboxyglutamic acid-containing protein, serum Gla-protein, S-BGP) level. 
Having been identified as a more accurate marker of bone formation than serum alkaline 
phosphatase and parathyroid hormone levels in dialysis patients (27, 41, 107, 144, 158), 
serum osteocalcin levels were compared and found to be different between the two groups 
as described above. Serum osteocalcin levels correlated positively with parathyroid 
hormone and alkaline phosphatase levels in this study as in other studies. In accordance 
with previous studies (27, 41, 55, 107, 158), serum osteocalcin levels were not correlated 
with ionized calcium, or total serum calcium levels in this investigation. 
Mean serum tartrate-resistant acid phosphatase level was significantly higher in 
black versus white patients in this study. This enzyme is released by osteoclasts during 
bone resorption (48, 119, 128). Therefore, it was used as an indirect marker of bone 
resorption. In this study, black patients had a higher mean tartrate-resistant acid 
phosphatase than the white patients. Furthermore, tartrate-resistant acid phosphatase levels 
correlated positively with osteocalcin and PTH levels. Therefore, our results are consistent 
with the fact that bone formation and bone mineralization are usually closely coupled. 
Taken together, these results suggest that black patients have a higher bone turnover 
rates than white patients (Table 7). The mean values for all four major bone turnover 
parameters in black subjects were nearly two standard deviations above the white subjects' 
means. Furthermore, in every bone turnover parameter measured, there was a higher 
percentage of black subjects with values above the upper limit of normal range than white 
subjects. These differences reached statistical significance for serum osteocalcin and 
average serum alkaline phosphatase levels. At this point, we have no evidence that there 
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are differences in the clearance of these molecules between the two racial groups. 
Therefore, these findings, taken as an aggregate, suggest that the black dialysis patients had 
higher bone turnover rates than white dialysis patients. This difference is likely to be in 
part due to black patients’ greater degree of secondary hyperparathyroidism. 
Possible Explanations of Higher iPTH levels in Black Patients 
Whether the greater degree secondary hyperparathyroidism is due to biological / 
genetic predisposition or to socioeconomic factors or both warrants further investigation. 
In this investigation, it is possible that the PTH secretion in black patients has a higher 
calcium set point or is more resistant to the suppressive effects of vitamin D. Racial 
differences in bone metabolism of normal subjects without renal failure have been studied. 
In the healthy population, black people in general have a 5-10% higher bone density (due to 
greater bone mineral content) than white people do (42), a difference which persists even in 
patients with chronic renal failure (110). This is partly due to a greater increase in bone 
growth during the pubertal spurt in black individuals than in white individuals (70). 
Because of the higher parathyroid hormone levels (11) and a lower bone turnover rate in 
normal black subjects (about 35% of that in white subjects). Bell, et al. suggested that the 
black people are more resistant to the bone resorptive effects of parathyroid hormone 
compared to white people (191). They further proposed that the greater bone mass 
developed during adolescence is preserved by a lower rate of bone turnover throughout 
adulthood (191). Moreover, normal black individuals also have a higher 1,25-vitamin D 
level and a lower osteocalcin level (11). Unfortunately, whether this relative resistance 
increases or decreases in chronic dialysis patients is unclear, and the exact link between 
genetics and bone metabolism remains to be proven and elaborated in this patient 
population. 
On the other hand, well known in this society is that socioeconomic factors can 
affect preventive care and early intervention, as well as patient education and compliance, 
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which in turn have major impacts on the progression of diseases to renal failure (32, 67, 
77, 150). In general, black subjects, compared to white subjects, in this patient population 
may be less educated about the health care system, thus diseases in black patients may be 
brought to the attention of medical professionals much later (67). In addition, black 
patients may be less educated about their diseases leading to poorer compliance (67). For 
instance, in hypertension and diabetes mellitus, the two most common causes of renal 
failure, early medical intervention and good patient compliance may delay the progression 
to renal failure and may perhaps influence further complications once the patient is on renal 
dialysis. Thus, it is possible that the greater degree of hyperparathyroidism observed in 
black subjects in our study is due to socioeconomic factors leading to less frequent use of 
measures to prevent hyperparathyroidism in black subjects as end stage renal disease 
develops or after starting on dialysis. 
Other Explanations 
Several possible confounding factors were considered in this comparison of the 
racial groups. There was no evidence that the groups differed in terms of age, length of 
time on dialysis, serum albumin level, average serum bicarbonate concentration, percent 
females, percent with low activity, percent with diabetes mellitus, or percent post subtotal 
parathyroidectomy. 
Aging has a large impact on calcium metabolism (21, 68, 153), and age is the most 
important determinant of bone density in a normal population. The decrease in bone 
density with increasing age may be a consequence of several age-related processes: 
decreased osteoblast function, decreased calcium absorption in both sexes especially after 
70 years of age, and increase in serum immunoreactive parathyroid hormone. The 
increased bone turnover at the tissue level with increasing age actually enhances bone loss 
because of the decreased osteoblastic function at the cellular level. In other words, 
although the number of bone remodeling units in the skeleton is increased, more bone is 
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removed than is subsequently replaced. However, the two group in our study had similar 
mean age. 
In recent years, the sex differences of bone metabolism and bone characteristics in 
the general population have been examined intensely. Compared to women within the 
same race, men tend to reach a higher peak bone density at skeletal maturity and maintain a 
heavier skeleton throughout life (111, 137). In addition, menopause accelerates bone loss 
in women. In our patient population, all women, except one white patient, were 
amenorrheic and were not receiving estrogen replacement therapy. Although men do not 
undergo the rapid physiological changes equivalent to menopause, gonadal function does 
decline gradually in some older men. Such hypogonadism is often associated with 
vertebral fractures. In light of these differences, this study took account the sex ratios in 
the two racial groups and showed no evidence of a statistical difference. 
The physical activity level relevant to this study was assessed by the percent of 
wheelchair-bound/bed-ridden subjects in each group because mechanical forces have been 
shown to promote osteoblast growth and activity, and prolonged inactivity immobilization 
to cause secondary osteoporosis as a result of remodeling imbalance (96). Therefore, 
wheelchair-bound/bed-ridden are expected to have a relatively lower bone turnover rate. 
However, the two groups in our study had similar average activity levels, as measured by 
percentage of patients that were wheelchair-bound/bed-ridden. 
Body mass indices of the two groups were considered since obese people are 
believed to have a slower rate of bone loss (95) and fewer spine fractures (114). Bell, et 
al. (12) also found that the obese non-dialysis subjects tended to have higher osteocalcin, 
plasma 1,25-dihydroxyvitamin D, and PTH levels and a lower serum 25-hydroxyvitamin D 
level. The two groups had similar body mass indices. 
The results cannot be explained by greater diabetic osteopenia in white patients 
since the black patients actually had a greater percentage with diabetes mellitus, though this 
difference did not reach statistical significance. As bone mass has been variously reported 
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to be increased (114), normal (47), or decreased (94, 95, 183) in the older, adult diabetic 
population, there is no consensus in the literature. In addition, these diabetics are usually 
obese. In a study of 79 white, postmenopausal, type II diabetics with age, 59.9±6.6 years 
(mean ± SD), similar to the age of our patient population, Johnston, et al. (84) found that 
compared to normals, postmenopausal white type II diabetics lost bone at a slower rate and 
had higher bone mass compared to normals not explained by obesity or glucose control 
alone, although the diabetics did have a higher mean body weight than the controls. 
However, more recently. Chew (31) found that in the adult population, generalized 
osteoporosis may accompany insulin-dependent diabetes mellitus if obesity is absent. 
Moreover, Andress, et al. (8) observed that diabetes is often associated with the failure of 
PTH to promote bone mineralization. Thus, the current thinking is that osteopenia is more 
often seen in diabetes mellitus than in the normal population. In this investigation, the 
difference in the percentages of diabetes mellitus in black (54.84%) and white (31.84%) 
subjects was considerable, although it did not reach statistical significance. Therefore, if 
either one group were to have a lesser degree of diabetic low bone turnover, the black 
patient group is more likely. Our results are therefore even more impressive in 
demonstrating that bone turnover was higher in black patients despite a greater number of 
diabetic patients in this group. 
Also important to consider was the percentage of subjects with subtotal 
parathyroidectomy in each group, since those with subtotal parathyroidectomy are expected 
to have a lower parathyroid hormone level than they would had without this surgical 
intervention. Short term effects of parathyroidectomy include alterations in plasma alkaline 
phosphatase activity and plasma osteocalcin level (187). Weinstein, et al. (190) found that 
the decrease in intact parathyroid hormone level after subtotal parathyroidectomy is 
associated with decreased mineralization and increased nonosteoblastic osteoid formation. 
After subtotal parathyroidectomy, some hemodialysis patients may convert osteitis fibrosa 
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to a low turnover osteomalacia which is poorly treatable. The two groups in our study had 
similar percentages of subjects with subtotal parathyroidectomy. 
Calcium Ingestion 
In our study, the overall frequency of hypercalcemic episodes among the patients in 
our study was only 8% as compared to 36% in Meric and Bia's investigation at the same 
dialysis unit three years ago. This difference might lead one to think that either the patient 
characteristics of the unit had changed since that time or that some other factors had played 
a role in decreasing the incidence of hypercalcemia in this unit. After reviewing the 
characteristics of our patient population, we did not find any major difference. For 
example, our subject population was 38% white subjects, compared to their 36% white 
subjects. Thus, the first of the two possibilities did not seem likely. 
However, the current management of the dialysis patients is very different from that 
at the time of Meric and Bia's study. They analyzed patients who had just been initiated on 
the high-dose calcium carbonate therapy and who had only minor or temporary 
modifications of their calcium doses in order to control their serum phosphate levels or to 
treat hypercalcemia if it occurred. Since then, management has changed to make 
hypercalcemic episodes less likely. For example, more than half of the patients in the unit 
are now on a low calcium bath (2.5 rather than 3.5 mEq/1). Furthermore, vitamin D 
supplements are not initiated until the patient is on a dose of calcium supplement that 
provides adequate phosphate binding. Because of these practices, the frequency of 
hypercalcemic episodes appears to be markedly reduced. In contrast to the patient 
population in Meric and Bia's study, ours reflect the success of such clinical manipulations 
to avoid hypercalcemia. 
From this perspective, it was not surprising to find a lower incidence of 
hypercalcemia in our study compared to their study. However, this does not imply that the 
ability to tolerate ingested calcium is necessarily similar in black and white dialysis patients 
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in our study. The two groups did have similar mean levels of serum calcium, ionized 
calcium, and serum phosphate-P. However, a look at the more subtle parameters of 
calcium tolerance revealed that there were differences in total calcium intake. 
Although the two groups had similar dietary calcium intakes, dialysate calcium 
concentration, oral 1,25-dihydroxyvitamin D doses, and plasma 1,25-dihydroxyvitamin D 
levels, the black patients were able to tolerate significantly higher elemental calcium doses 
(in the form of calcium carbonate) than the white patients. The results suggest that black 
patients had either lesser passive reabsorption of oral calcium or lesser sensitivity of the 
action of vitamin D. The fact that the mean dietary phosphate intake and mean serum 
phosphate levels were comparable in the two racial groups implied that the two dialysis 
patient groups required similar amounts of phosphate-binding. At this time, calcium 
carbonate is preferred as a phosphate binder over aluminum hydroxide to avoid aluminum 
overload. During the present investigation, the first medical intervention in hypercalcemic 
patients taking calcium carbonate was to discontinue or lower the dose of calcium 
carbonate. The fact that elemental calcium doses from calcium carbonate tended to correlate 
negatively with elemental aluminum doses in the form of aluminum hydroxide among the 
subjects in this study suggests that patients on relatively lower doses of calcium carbonate 
are most likely to be those who cannot tolerate a higher dose. Therefore, these results 
suggest that black hemodialysis patients, compared to white patients, have greater ability to 
tolerate ingested calcium without becoming hypercalcemic (although the frequency of 
hypercalcemia is the same). 
Slatopolsky, et al. (170) proposed that hypercalcemia on calcium-containing 
phosphate binders resulted from the high doses (greater than 12g) of calcium carbonate 
used. Gonella, et al. (74) suggested that those who developed hypercalcemia while on 
calcium carbonate had higher levels of vitamin D metabolites which would enhance calcium 
absorption. However, hypercalcemic episodes in other studies were often not related to 
high calcium carbonate doses (66, 71, 101, 116). Of the 41 dialysis patients on high-doses 
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of calcium carbonate in Mactier's study (101), the 11 who became hypercalcemic did not 
receive a higher dose than the rest. This observation suggests that the difference in the 
ability to tolerate calcium carbonate might not stem directly from difference in calcium 
absorption from the gut. In order to examine this issue, we looked at several factors 
relevant to calcium absorption. 
Plasma level of 1,25-dihydroxyvitamin D is regarded as a major factor in the active 
absorption of calcium (50). While some studies have found that the decreased plasma 
1,25-dihydroxyvitamin D level in chronic renal failure patients reduces calcium absorption 
in the gut (18, 39, 188), others have shown that intestinal calcium absorption is preserved 
in a rather unpredictable fashion from one patient to the next and perhaps supranormal 
absorption in the presence of severe uremia (118, 148). Therefore, variability in plasma 
1,25-dihydroxyvitamin D levels may be present to account for the difference in calcium 
absorption. In the healthy population, black subjects appeared to have resistant to the 
intestinal calcium absorption effects of 1,25-dihydroxyvitamin D in one study (46), but 
such resistance was not found in another study comparing black and white adolescents 
(13). Whether this difference occurs in the chronic hemodialysis patients is unknown, and 
whether it holds true for calcium carbonate ingested as phosphate binders is also unclear. 
Studies have shown that a low calcium meal can nearly saturate the vitamin D-dependent 
active absorption of calcium in the gut of hemodialysis patients (135), so this difference 
found in the healthy subjects may not apply to this current study. Although their active 
calcium absorption abilities may be impaired, passive calcium absorption in chronic renal 
failure patients is believed to be intact (34, 135). Since the two groups in the present 
investigation were similar in their dietary calcium intake and the black patients had a higher 
elemental calcium dose in the form of calcium carbonate, there is no evidence in this study 
that the black patients absorbed less calcium via the vitamin D-dependent active process, 
although that possibility still exists. Many studies have suggested that the increased 
calcium absorption during calcium supplementation may be attributable to vitamin D- 
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independent mechanisms (72, 135, 175). Shiekh, et al. (160) found that passive calcium 
absorption correlated linearly with luminal calcium concentration which varied with calcium 
intake. With large doses of calcium carbonate (20g), absorption was the same in patients 
with and without renal disease (34). Therefore, the average amounts of calcium passively 
absorbed by the subjects were expected to correlate roughly with their mean calcium doses. 
Since the black patients in our study tolerated a higher calcium dose from calcium 
carbonate, their overall intestinal calcium absorption was probably greater than white 
patients' on the basis of passive absorption alone. Thus, neither intestinal calcium 
absorption nor calcium carbonate dosage is likely to account for the greater ability to 
tolerate ingested calcium in the black compared to the white patients. 
In the chronic hemodialysis patients, it remains possible that differences in intestinal 
calcium absorption contribute to the greater calcium ingestion tolerated by black patients. 
This question is best answered by measuring calcium absorption directly with stringent 
records of intake and output or with oral ^^Ca studies, rather than from the less reliable 
dietary recalls by patients. 
In summary, the black hemodialysis patients in this study appear to have a greater 
degree of secondary hyperparathyroidism and a higher bone turnover rate than the white 
patients. Whether this difference is due to biological/genetic predisposition or is due to 
socioeconomic factors affecting preventive care and early intervention warrants further 
investigation. 
The association between high bone turnover rate and decreased likelihood of 
hypercalcemia in dialysis patients has been documented (116). The fact that black patients 
in our study had a greater calcium tolerance may well be explained by their higher bone 
turnover rate, which allowed serum calcium to be deposited into bone more quickly. The 
lack of linear correlation between elemental calcium dose and parameters of bone turnover 
does not disprove this explanation, as the relationship between the two may not be strictly 
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linear. Of course, further confirmation of this explanation rests on bone biopsy, the 
definitive measure of bone turnover. In any case, the black hemodialysis patients appear to 
be able to tolerate a higher dose of calcium carbonate than white patient without 
succumbing to the side effect of hypercalcemia. 
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VI. Conclusion 
In comparison to the white hemodialysis patients, black patients had a higher bone 
turnover rate as reflected by a higher mean serum tartrate-resistant acid phosphatase level 
and mean intact parathyroid hormone level (suggesting a greater degree of secondary 
hyperparathyroidism), as well as by a greater percentage of the group having an elevated 
osteocalcin level and a greater percentage of the group having an elevated average alkaline 
phosphatase level. Moreover, the high degree of positive correlation between osteocalcin 
and tartrate-resistant acid phosphatase levels suggests that the bone formation and 
reabsorptions rates of these hemodialysis patients were closely coupled as seen in normal 
bone metabolism and in high turnover states of hyperparathyroidism. These results are 
consistent with the explanation that the higher bone turnover rates in black patients make 
available their bones as a reservoir for any excess calcium in the circulation, rather than 
allowing them to become hypercalcemic. Whether the greater bone turnover rate and 
greater degree of secondary hyperparathyroidism in blacks are the results of genetic 
predisposition or the results of social factors affecting preventive care and early intervention 
warrants further research. 
While requiring similar amounts of phosphate-binding, the two patient group 
ingested different amounts of calcium carbonate, which is preferred over aluminum 
hydroxide as a phosphate binder. Compared to the whites, black patients tended to have a 
higher mean elemental calcium dose (in the form of calcium carbonate) and did have a 
significantly higher percentage receiving over 1 gram of elemental calcium in the form of 
calcium carbonate. However, the two groups had similar mean total serum calcium, 
ionized calcium, and dialysate calcium concentrations. It appeared then that the black 
patients had a greater tolerance for calcium carbonate (without becoming hypercalcemic or 
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having to lower the dialysate calcium concentration) than the white patients. This greater 
calcium tolerance in black patients was probably not a result of a decreased intestinal 
absorptive capacity because 1) there was no evidence to show that the groups differed in 
terms of dietary calcium intake and plasma 1,25-dihydroxy vitamin D level, 2) vitamin D- 
dependent calcium absorption tends to be saturated at low calcium intakes in chronic renal 
failure so that any vitamin D resistance at the gut level in black patients probably plays a 
minor role, if any, and 3) the black patients had a higher mean calcium dose from calcium 
carbonate than the white patients suggesting a greater amount of calcium absorbed via 
passive vitamin D-independent mechanism. Therefore, the black patients' higher tolerance 
for the calcium from calcium carbonate probably cannot be attributable to a reduction of 
intestinal calcium absorption and certainly not to a lower calcium carbonate dose. 
However, these results are consistent with the idea that the blacks' higher bone turnover 
rate renders them the greater calcium tolerance. 
At this time, there have not been any reports on racial differences in bone turnover 
and calcium tolerance in chronic hemodialysis patients. The findings of this study remain 
to be confirmed and extended by future research. Whether the greater degree of 
hyperparathyroidism in the black patient group is a consequence of genetic or social factors 
also deserves further investigation. 
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VII. Tables 
Table 1: Factors Contributing to the Development of 
Secondary Hyperparathyroidism in Renal Insufficiency (35) 
1. Phosphate retention 
2. Altered vitamin D metabolism 
3. Skeletal resistance to the calcemic action of parathyroid hormone 
4. Altered feedback regulation between ionized calcium level and 
parathyroid secretion 
5. Impaired degradation of parathyroid hormone by the kidneys. 
I 
I 
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Table 2: Causes of Hypercalcemia (178) 
1. Hyperparathyroidism 
2. Cancer-associated hypercalcemia 
3. Hypervitaminosis D 
4. Sarcoidosis and other granulomatous diseases 
5. Idiopathic hypercalcemia of infancy 
6. Hypervitaminosis A 
7. Hypercalcemic periostitis 
8. Milk-alkali syndrome 
9. Immobilization (extensive skeletal immobilization in normal young 
people and prolonged bed rest in patients with osteolytic metabolic 
bone disease) 
10. Recovery from acute renal failure 
11. Thiazide diuretic-associated hypercalcemia 
12. Other endocrine causes of hypercalcemia (Hyperthyroidism, Adrenal 
insufficiency, etc) 
13. Low turnover osteomalacia due to aluminum accumulation (Dialysis 
osteomalacia, total parenteral nutrition) 
14. Familial Hypocalcuric hypercalcemia 
15. Other mechanisms: theophylline, lithium, etc 
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Table 3: Causes of Hypercalcemia in Dialysis Patients (35) 
1. Severe secondary hyperparathyroidism 
2. Low turnover osteomalacia due to aluminum accumulation 
3. Treatment with calcium-containing phosphate binders (calcium 
carbonate, calcium acetate, calcium citrate) and/or with vitamin D 
sterols* 
4. High dialysate calcium concentration 
5. Endogenous production of 1,25-dihydroxyvitamin D (sarcoidosis, 
tuberculosis, or other granulomatous diseases) 
6. Malignancy or neoplasms 
7. Immobilization* 
* often coexists with #1 and #2 and may be the precipitating or 
aggravating event in the manifestation of hypercalcemia. 
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Table 4: Selection of Subject Population 
and Its Sex and Racial Distributions 
58 Fifty-eight patients chronically hemodialyzed at the Yale-New Haven Dialysis Unit. 
-2 Two patients were Hispanic but were HIV-negative and HBsAg-negative. 
-1 One patient was HBsAg-positive and Hispanic. 
-1 One patient was HIV-positive. 
-4 Four patients did not give oral consent to participate in this study. 
50 Fifty HIV-negative and HBsAg-negative, black and white patients who were 
chronically hemodialyzed at the Yale-New Haven Dialysis Unit gave oral consent 
and participated in this study. 
16 Black females 6 White females 
15 Black males_ 13 White males 
31 Black subjects 19 White subjects 
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Table 6: Parameters of Bone Turnover Rate compared by 
Student's t-test and chi-square / Fisher's exact test 
Parameters 1 Blacks 
1 mean ± SE 
1 N=31 
1 
Whites 
mean ± SE 
N=19 
d value1 2 
t-test 
% of Blacks 
N=31 
% of Whites 
N=19 
n-value1 
chi-square/ 
Fisher’s 
dialyzer membrane surface area (m^) 
1 
1 1.16 
1 
1.18 
- 
ionized calcium (mg/dl) 
1 
1 4.81 ± 0.09 4.81 ± 0.13 - 
total calcium (mg/dl) 1 9.4 ± 0.18 9.2 ± 0.23 
- 
hypercalcemia during the 3 months of review 1 
1 
6.45 10.53 
- 
phosphate-P (mg/dl) 
1 
1 5.48 ± 0.40 
1 
5.87 ± 0.68 
- 
alkaline phosphatase (U/l) 
1 
1 153 1 20.8 114 122.0 
- 
alkaline phosphatase level > 114U/1 1 
1 
54.84 31.58 
- 
osteocalcin (ng/ml) 
1 
1 81.32 1 12.82 48.49 1 15.32 - 
osteocalcin level > 25 ng/ml 1 
1 
77.42 47.37 0.0290 
tartrate-resistant acid phosphatase^ (U/l) 
1 
1 4.4 ± 0.28 
1 
3.3 1 0.27 0.0166 
tartrate-resistant acid phosphatase^ > 4.2U/1 1 
1 
43.33 22.22 ... 
intact PTH (pg/ml) 
1 
1 273 ± 56.5 118 1 39.1 0.0286 
intact PTH level > 65pg/ml 1 
1 
64.52 AIM ... 
serum l,25-(OH)2 D level (pg/ml) 
1 
1 30.7 ± 2.69 25.6+ 1.25 - 
serum l,25-(OH)2 D level > 65pg/ml 1 
1 
1 
3.23 0.00 ... 
1 p values greater than 0.05 are not listed. 
2 N for tartrate-resistant acid phosphatase is 30/31 for blacks and 18/19 for whites. 
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Table 7: Parameters of Calcium Tolerance compared by 
Student's t-test and chi-square / Fisher's exact test 
Parameters 1 Blacks 
1 mean ± SE 
1 N=31 
1 
Whites 
mean ± SE 
N=19 
p value1 2 3 4 5 
t-test 
% of Blacks 
N=31 
% of Whites 
N=19 
Serum Calcium 1 
ionized calcium (mg/dl) 1 4.81 ± 0.09 4.81 ± 0.13 
— 
serum calcium (mg/dl) 1 9.4 ±0.18 9.2 ± 0.23 
- 
hypercalcemia during the 3 months reviewed i 
i 
6.45 10.53 
Dialysate Calcium 
i 
i 
dialysate calcium concentration (mEq/l) 1 3.1 ± 0.09 3.0 ± 0.18 
% with dialysate calcium cone = 3.5mEq/l i 
i 
54.84 52.63 
Calcium Intake11 
i 
i 
dietary calcium (mg/day) 1 493 ±56.0 522 ±71.7 
— 
dietary calcium intake > 600mg/day 1 28.57 25.00 
elemental calcium dose (mg/day) 1 2330 ± 366.4 
1 
1273 ±312.9 0.05 
on dose > lg elemental calcium1 per day i 74.19 42.11 
on dose > 2g elemental calcium-1 per day i 41.94 15.79 
% on calcium-containing phosphate1 binder i 
i 
80.65 '68.42 
1,25-dihydroxyvitamin D 
1 
1 
oral 1,25-dihydroxyvitamin D dose (pg/day) 1 0.15 ±0.03 0.09 ± 0.03 — 
% on oral 1,25-dihydroxy vitamin D 1 
1 
48.39 31.58 
% on oral vitamin D dose > 0.25 pg/day 1 9.68 5.26 
plasma l,25-(OH)2 D level (pg/ml) 1 30.7 ± 2.69 25.6 ± 1.25 - 
plasma l,25-(OH)2 D level > 65pg/ml 1 
1 
3.23 0.00 
Phosphate Intake'1 
1 
1 
dietary phosphorus (mg/day) 1 867 ± 53.2 
1 
926 ± 111 
Aluminum Intake1 
1 
1 
elemental aluminum dose (mg/day) 1 405.7 ± 107.6 673.4 + 201.4 — 
% on aluminum-containing phosphate binder 1 38.71 47.37 
% on dose >lg elemental aluminum per day 1 25.81 42.11 
% on dose >2g elemental aluminum per day 1 3.23 5.26 
no phosphate binder 1 
1 
3.23 0.00 
1 p values greater than 0.05 are not listed. 
2 Dietary calcium intakes were obtained for 21/31 black patients and 12/19 white patients. 
3 Administered in the form of calcium carbonate 
4 Diety phosphate intakes were obtained for 21/31 hlack patients and 12/19 white patients. 
5 Administered in the form of aluminum hydroxide 
p value1 
chi-square/ 
Fisher's 
0.0230 
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Table 8: Linear Correlations 
Parameter 1 Parameter 2 Pearson 
correlation 
coefficient 
p value sample 
size 
(N) . 
osteocalcin & intact PTH +0.65484 0.0001 50 
osteocalcin & TRAP +0.59522 0.0001 48 
osteocalcin & alkaline phosphatase +0.40372 0.0036 50 
TRAP & intact PTH +0.41709 0.0032 48 
intact PTH & body mass index +0.41623 0.0033 50 
elemental calcium dose & serum 1,25-dihydroxy vitamin D +0.47367 0.0005 50 
elemental calcium dose & oral 1,25-dihydroxyvitamin D +0.45854 0.0008 50 
serum 1,25-dihydroxyvitamin D & total serum calcium +0.34120 0.0153 50 
Elemental calcium doses of calcium carbonate did not correlate with any parameter of bone turnover. 
Serum calcium level is not correlated with either elemental calcium dose or dietary calcium intake. 
Table 9: Correlations found by Meric, F., et al. (116) 
Parameter 1 Parameter 2 Pearson 
correlation 
coefficient 
p value sample 
size 
(N) . 
osteocalcin & PTH + 0.8 < 0.001 28 
serum calcium & alkaline phosphatase - 0.38 0.045 28 
osteocalcin & alkaline phosphatase + 0.46 < 0.001 28 
Osteocalcin levels did not correlate with mean or peak serum calcium concentration on calcium carbonate 
therapy. 

VIII. Figures 
Figure 1: Distributions and Means of Serum 
Tartrate-Resistant Acid Phosphatase Levels 
of Black and White Patients 
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Figure 2: Distributions and Means of Serum 
intact Parathyroid Hormone (PTH) Levels of 
Black and White Patients 
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Figure 3: Distributions and Means of Serum Alkaline 
Phosphatase Levels* of Black and White Patients 
Blacks Whites 
* Plotted are values and calculations from the patients' 
serum alkaline phosphatase levels at the time of study. 



300 
275 
250 
225 
200 
175 
150 
125 
100 
75 
50 
25 
0 
51 
Figure 4: Distributions and Means of Serum 
Osteocalcin Levels of Black and White Patients 
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Figure 5: The Percentages of Black and White 
Patients with Elevated* Serum Osteocalcin Levels 
52 
80 
Blacks Whites 
* Serum osteocalcin levels above the upper limit 
for normal range (25ng/ml) were considered elevated. 
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Figure 6: Distributions and Means of Daily 
Elemental Calcium Dose* of Black and White Patients 
53 
Blacks Whites 
* Daily elemental calcium doses were calculated from 
the patients' prescribed dialy calcium carbonate doses 
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Figure 7: The Percentages of Black and White Patients 
with Daily Elemental Calcium Dose* Above 1 Gram 
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p = 0.0230 
Whites 
* The daily elemental calcium doses were calculated from 
the patients' prescribed daily doses of calcium carbonate. 
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